Default Category
-
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
Hamermesh, Richard G.; Kucherlapati, Raju; Gordon, RachelCase HBS-810066-EEntrepreneurshipIn May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had received approval several years prior. Moreover, Vectibix had also received Food and Drug Administration approval in 2006. During additional trials, Amgen has learned that the Vectibix...Starting at €8.20
-
The Indego Africa Project (Spanish Version)
McGinn, Kathleen L.; Gordon, RachelCase HBS-914S10Dos abogados jóvenes que se encuentran y comienzan a construir el Proyecto África Indego, una asociación de ONG con cooperativas de mujeres en Ruanda. Indego conecta las cooperativas en el mercado minorista internacional de productos artesanales hechos a mano, ayuda a las cooperativas construyen su capacidad de negocio, y desarrolla y ofrece formación en el aula en la vida y habilidades de negocio para los miembros de la cooperativa. En el moment...Starting at €8.20
-
Storming into the U.S. Market (Spanish version)
Bartlett, Christopher A.; Gordon, Rachel; Lafkas, JohnCase HBS-918S10StrategyThe RoboTech case describes the challenges facing the CEO of a small, Singapore-based industrial robotics company that decides to diversify away from its core industrial robot business by leveraging its expertise into the medical-devices industry. It launches an innovative product (a specialized surgical robot) in an unfamiliar market segment (spinal surgery) and decides to enter the unfamiliar, distant U.S. healthcare market, which is characteri...Starting at €8.20
-
Intrapreneurship within FLG, Inc. (Spanish version)
Garvin, David A.; Gordon, RachelCase HBS-918S11EntrepreneurshipThis case follows Jenica Fletcher as she rebuilds her company's guitar strings division from the ground up. Convinced that she could turn the division around if given complete independence from corporate headquarters, Fletcher relocated the group, rebranded it as Malenti Strings, repositioned the guitar strings as high-performance products, and transformed Malenti into a fast-growing, profitable business. The case traces Fletcher's key steps in...Starting at €8.20
-
Apple Inc. in 2012 (Spanish version)
Yoffie, David B.; Rossano, PenelopeCase HBS-713S04Strategyhe had changed Apple from a company near bankruptcy to one of the largest and most profitable companies in the world. Moreover, he had revolutionized several industries in the process, including music, phones, and computer tablets. The 'Apple Inc. in 2012' case explores Steve Jobs' successes and the challenges facing his successor, Tim Cook. Could Cook continue to revitalize the Macintosh? With iPod sales declining for four straight years, would...Starting at €8.20
-
Differences at Work: Alex (A) (Spanish version)
Sucher, Sandra J.; Gordon, RachelCase HBS-408S50Leadership and People ManagementIn Differences at Work: Alex (A), HBS Case No. 9-408-011 Alex has been asked an inappropriate question by the interviewer at an interview for his dream job. How will Alex handle the situation? Should he accept the position is offered?Starting at €8.20
-
Ahold versus Tesco--Analyzing Performance
Srinivasan, Suraj; Rossano, PenelopeCase HBS-113040-EAccounting and ControlThe case relates to understanding and comparing the performance of two leading retail companies-Ahold and Tesco. The case introduces the tools of Dupont and Modified Dupont Decomposition. While performance as measured by return on equity has been similarStarting at €8.20
-
Alcoa's Bid for Alcan (A)
Healy, Paul M.; Rossano, PenelopeCase HBS-114029-EAccounting and ControlIn spring 2007, Alcoa CEO Alain Belda was concerned about the company's market position in light of increased competition from developing markets. China's recent entry into the aluminum market was affecting both supply and demand. Furthermore, downstream and upstream product was coming on-line from other parts of the world, including Russia. As a result, Alcoa had lost its historical market dominance and stock premium. Belda was convinced that fo...Starting at €8.20
-
Alcoa's Bid for Alcan (B)
Healy, Paul M.; Rossano, PenelopeCase HBS-114030-EAccounting and ControlIn spring 2007, Alcoa CEO Alain Belda was concerned about the company's market position in light of increased competition from developing markets. China's recent entry into the aluminum market was affecting both supply and demand. Furthermore, downstream and upstream product was coming on-line from other parts of the world, including Russia. As a result, Alcoa had lost its historical market dominance and stock premium. Belda was convinced that fo...Starting at €5.74
-
Adnexus Therapeutics, Inc.: Considering the Exit
Sato, Vicki L.; Gordon, RachelCase HBS-609015-EService and Operations ManagementDr. John Mendlein, CEO of Adnexus Therapeutics Inc., (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six month collaboration or continue with Adnexus' planned IPO.Starting at €8.20